ReviewTherapeutic advances in medical oncology2023

What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?

Robert B Cameron et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.